A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study
Authors Juvelekian G, El-Sorougi W, Pothirat C, Yunus F, De Guia T, Kuo H, Basu Patnaik S, Pilipovic V
Received 18 February 2015
Accepted for publication 2 June 2015
Published 5 October 2015 Volume 2015:10(1) Pages 2109—2120
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Richard Russell
Georges Juvelekian,1 Waleed El-Sorougi,2 Chaicharn Pothirat,3 Faisal Yunus,4 Teresita De Guia,5 Han-Pin Kuo,6 Shalma Basu Patnaik,7 Virginia Pilipovic8
1St Georges Hospital University Medical Center, Ashrafieh, Beirut, Lebanon; 2Chest Department, Faculty of Medicine, Helwan University, Cairo, Egypt; 3Division of Pulmonary and Critical Care, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 4Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia, Persahabatan Hospital, Jakarta Timur, Indonesia; 5Department of Pulmonary Medicine, Philippine Heart Center, Quezon City, Philippines; 6Linkou Chang Gung Memorial Hospital, Taoyuan Hsien, Taiwan, ROC; 7Novartis Healthcare Pvt Ltd, Rangareddy, Telangana, India; 8Novartis Pharma AG, Basel, Switzerland
Aim: INFLOW (INdacaterol eFfectiveness and utiLizatiOn in COPD: real World evaluation) was a prospective, noninterventional study assessing the effectiveness and safety of long-acting bronchodilators in patients with chronic obstructive pulmonary disease (COPD) from the Middle East, Asia, and South Africa.
Methods: Patients newly prescribed or switched to indacaterol or other long-acting β2-agonist (LABA), or tiotropium (monotherapy or in combination) were evaluated over 6 months. The primary endpoint was the clinical COPD questionnaire overall score at the end of the study.
Results: Data were analyzed from 1,710 patients (mean postbronchodilator forced expiratory volume in 1 second, 59% predicted) who received indacaterol (n=1,179), other LABA (n=68), tiotropium (n=271), indacaterol plus tiotropium (n=167), or other LABA plus tiotropium (n=25). Across treatments, clinical COPD questionnaire overall score improved from baseline by 0.81–1.26 points (all P<0.0001), 63%–84% of patients were satisfied/very satisfied, and physicians rated effectiveness as good/very good in 63%–80% of cases. The indacaterol inhaler was rated easy/very easy to use by the majority of patients, and physicians considered its use clearly understood by most patients. All treatments had acceptable tolerability.
Conclusion: In real life clinical practice across a diverse region, indacaterol and other long-acting bronchodilators improved health status and were well regarded by patients and physicians.
Keywords: long-acting bronchodilator, indacaterol, chronic obstructive pulmonary disease, noninterventional study, Middle East, Asia
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]